The samples were classified into three experimental groups based on a clinical diagnostic report provided by the Netherlands Brain Bank/NeuroBiobank Born-Bunge and immunohistochemical analysis of Aβ and hyperphosphorylated tau (PHF-tau): CTR (no dementia, absence of Aβ plaques and PHF-tau, n = 6), CTR with plaques (CTR+, no dementia, presence of Aβ plaques and/or PHF-tau, n = 9), and AD (dementia, AD diagnosis, presence of Aβ plaques and/or PHF-tau, n = 11). Here, MAPT is linked to Alzheimer disease.